Single time point measurements of traditional cardiovascular risk factors (RFs) show strong associations with future cardiovascular event risk. In line with this concern, a group of researchers from the PROG-IMT consortium has made an interesting observation: average measurements of RFs assessed at separate time points ((RF1-RF2)/2), but not 'progression' between the measures (defined as the difference (RF2-RF1)), predict future cardiovascular risk. This observation challenges our traditional practice of risk prediction, and the reasons for it are likely to be multifactorial. First, as indicated by the authors, recent treatment for a RF such as statin has become so potent and widespread in many populations that measured RF tends to reflect more 'treated' values, which is likely to weaken its predictive property as compared with 'non-treated' values in the past. Second, the second measurement (RF2) may not be so different from the first measurement (RF1) because of a relatively stable lifestyle and/ or biological condition over the two time points. This would make the regression to the mean phenomena come into play for the difference (RF2-RF1), leading to a low signal-to-noise ratio. In conclusion, the researchers from the PROG-IMT consortium have raised a very noteworthy and valuable point, that the predictive property of some RFs may have lessened in recent years.
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Benefits of exercise training on blood pressure control
The importance of risk factor control including sedentary habits in the prevention and treatment of cardiovascular disease is well established. 1, 2 In the current issue perhaps the largest and most thorough meta-analysis to date on the impact of exercise training (ET) on blood pressure in people with hypertension is presented: it is also comparing the anti-hypertensive effects of ET versus modern day pharmacological intervention.
In an analysis of 93 randomised controlled trials (RCTs) (32,404 individuals, mean age in RCTs 39-70 years), in 32 of those trials, both ET and medications, together, effectively lowered blood pressure compared with controlled conditions. Although the point estimate suggested that the anti-hypertensive medications were more effective than ET, there was insufficient evidence to suggest that first-line anti-hypertensive medications (including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists and thiazide-like diuretics) significantly reduced blood pressure to a greater extent than ET intervention did, supporting the idea that vigorous non-pharmacological therapy, including ET, should be considered as first-line therapy for at least mild arterial hypertension.
Cognitive behavioural therapy reduces anxiety in implanted cardioverter defibrillator patients
Psychosocial factors can be considered common risk factors in heart disease and significantly deteriorate patient-reported outcomes. 3 One of these psychosocial factors is anxiety. It has been demonstrated that implanted cardioverter defibrillator (ICD) patients with anxiety disorders present an increased risk in mortality compared with patients without anxiety. 4 Several pathways, such as behavioural or biological mechanisms, relating to how mental health and heart disease are linked, have been proposed.
A randomised trial has here compared the efficacy of cognitive behavioural therapy (CBT) to usual care in patients with an ICD for reducing symptoms of anxiety. The study demonstrated that CBT treatment on top of usual care reduced the level of symptoms of anxiety. CBT techniques included analysis of the problem, psychoeducation, restructuring of negative automatic thoughts, behavioural experiments and home assignments, carried out by trained nurses who were supervised by a mental health specialist. Hence, it is concluded that an accurate assessment of the mental health status of any patient should be considered by the healthcare provider and, in case, evidence-based interventions such as CBT or pharmacology. From a patient's perspective it becomes less intrusive if medical personnel with an established patient relationship (such as medical doctors or qualified nurses) perform screening for mental health issues on a routine basis.
Mitral valve prolapse, a familial condition
With a prevalence of 1%, mitral valve prolapse (MVP) is commonly encountered in an unselected community sample. Clinically silent MVP with a benign course is a common scenario. However, an estimated subset of 7% of patients develop haemodynamically significant MVP-related regurgitation in which hypertension is a known accelerating factor/stressor on top of genetically susceptible valves and chordae. 5 A 1% prevalence of MVP in the community was previously demonstrated, but the offspring of patients with MVP present a significantly higher (5.4%) absolute risk of MVP. 5 Here the heritability of MVP was investigated in a smaller (n ¼ 385) but more targeted subset of index patients with a more severe phenotype of mitral regurgitation referred for surgical repair. Based on self-reported information of the index patients, familial occurrence was significant and ranged from 8% in relatives of patients with the fibroelastic-deplete phenotype, to 26% in relatives of patients with the Barlow phenotype. Of note, familial MVP was also found to correlate with a positive family history of sudden cardiac death, which underscores the clinical relevance of the arrhythmic complications of MVP. This paper advocates screening family members in such a referral-type population of MVP patients.
Cognitive impairment in acute coronary syndrome
Patients with high adherence to secondary prevention medication have a significantly reduced risk of all-cause mortality and of major adverse cardiovascular events. There is a variety of influences which may affect a patient's ability to make these modifications, including cognitive factors. Cognitive impairment can cause widespread difficulties with memory, language, attention, concentration, task completion and decision-making, which may significantly affect a patient's ability to initiate lifestyle changes. 6 Here a systematic review up until March 2019, in patients with acute coronary syndrome (ACS), found a prevalence of cognitive impairment of between 9% and 85% dependent on the severity of cognitive impairment assessed and the time when the assessment took place.
Furthermore, it appeared that verbal fluency, memory and language domains are most affected. This review certainly leaves the reader feeling that there is an important aspect of post-ACS care that is being missed in most patients. However, before screening for cognitive impairment in all ACS patients can be implemented, there needs to be further research to establish factors such as the optimal time for the screening and which tool should be used.
Secondary prevention: first of all, address the basics
Recent pivotal studies in secondary prevention have focused on adding novel pharmacological strategies, such as intensifying antithrombotic therapy, lowering lipid levels, improving glycaemic control and addressing inflammation, to reduce the high residual risk. Although some of these strategies have been shown to improve outcomes, they add costs and potential adverse events. Despite the strong evidence on the importance of risk factors in primary prevention, there is a lack of robust data showing whether the status of potentially modifiable risk factors still affects outcomes in patients who are at very high risk, and who receive state-of-the-art secondary prevention therapy.
An analysis presented here demonstrates that cardiovascular risk factor status and antithrombotic therapy have an independent and additive effect on cardiovascular outcomes in high-risk patients. In a secondary analysis of the COMPASS trial, patients were stratified according to the number of insufficiently controlled and potentially modifiable cardiovascular risk factors. Despite the use of secondary prevention therapies, the number of risk factors at baseline was still a powerful predictor of subsequent vascular events. Patients with a lower number of cardiovascular risk factors showed a lower annual incidence of cardiovascular events. This study encourages the physician to increase further efforts to control modifiable risk factors, first of all.
Pre-participation cardiovascular evaluation of young athletes: role of exercise stress test
The primary scope of pre-participation cardiovascular evaluation (PPE) is to identify silent cardiac diseases that may be associated with exercise-related sudden cardiac arrest or death. In 2016, the European Heart Rhythm Association and the European Association of Preventive Cardiology published a consensus statement on PPE and the panel recommended to consider PPE in individuals performing regular, intense exercise, after proper information of both its benefits and limitations. 7 The Italian PPE protocol differs from the European recommendation by including a constant load electrocardiogram (ECG) stress test (EST). In this issue of the journal, Alessandro Zorzi and colleagues studied EST in 10,985 consecutive non-professional athletes (median age 15 years) undergoing annual PPE: 9% of the athletes had abnormal findings, 4% were detected with medical history, physical examination or resting ECG alone and another 5% only during EST. Compared with routine PPE, the addition of EST increased the diagnostic yield by 75%. However, EST resulted in an additional 470 false positive cases, reducing the positive predictive value of PPE from 6.9% to 5.5% (-20%). Most importantly, the data of Zorzi and colleagues add to the evidence that cardiac diseases at risk of sudden cardiac death are rare in young athletes, even if sophisticated screening tools are used. This is reassuring for athletes, their families and trainers. Some athletes may have an indication to sweat during an EST, but most of them should safely sweat during competitions.
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